Keeping score on psychiatric drug effects: Is mefloquine safe for malaria chemoprophylaxis?

Journal of Pharmacy Technology

Volumn 22, Issue 1, 2006, Pages 32-41

  Willmore, Catherine B ^a,b   Ayesu, Linda W ^a  

^a UNIVERSITY OF MARYLAND   (United States)

^b OHIO NORTHERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMODIAQUINE; ANTIMALARIAL AGENT; ARTEMETHER; ATOVAQUONE PLUS PROGUANIL; CHLOROQUINE; CHLOROQUINE PLUS PROGUANIL; DAPSONE; DOXYCYCLINE; FANSIDAR; MEFLOQUINE; MEPACRINE; PRIMAQUINE; PROGUANIL; QUINOLINE DERIVATIVE; UNCLASSIFIED DRUG;

AGGRESSION; AGITATION; AGRANULOCYTOSIS; ANXIETY DISORDER; ARMY; ARTICLE; AUDITORY HALLUCINATION; BODY WEIGHT; CAREGIVER; CHEMOPROPHYLAXIS; CLINICAL TRIAL; CONCENTRATION LOSS; CONSULTATION; CONVULSION; DELUSION; DEPRESSION; DIZZINESS; DRUG COST; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; EMBASE; EYE PAIN; FOLLOW UP; GRAND MAL EPILEPSY; GRAND MAL SEIZURE; HEADACHE; HEARING DISORDER; HIGH RISK POPULATION; HUMAN; INSOMNIA; MALAISE; MALARIA; MEDLINE; MEMORY DISORDER; MENTAL DISEASE; MENTAL INSTABILITY; MIGRAINE; MOOD DISORDER; MOTOR NEUROPATHY; MUSCLE SPASM; MUSCLE WEAKNESS; MYALGIA; NEUROLOGIC DISEASE; NEUROSIS; NEUROTOXICITY; NIGHTMARE; NONHUMAN; PANIC; PARANOIA; PARESTHESIA; PATIENT COUNSELING; PHARMACIST; PHYSICIAN; PSYCHOSIS; RESTLESSNESS; RISK BENEFIT ANALYSIS; SEIZURE; SENSORY DYSFUNCTION; SENSORY NEUROPATHY; SIDE EFFECT; SPEECH DISORDER; STEVENS JOHNSON SYNDROME; STRESS; SUICIDE; TENSION HEADACHE; THROMBOCYTOPENIA; TINNITUS; TOURISM; VERTIGO; VESTIBULAR DISORDER; VIOLENCE; VISUAL DISORDER; VISUAL HALLUCINATION;

EID: 32544451133     PISSN: 87551225     EISSN: None     Source Type: Journal    
DOI: 10.1177/875512250602200106     Document Type: Article

References (109)

1. Schmidt LH, Crosby R, Rasco J, Vaughan D. Antimalarial activities of various 4-quinolonemethanols with special attention to WR-142, 490 (mefloquine). Antimicrob Agents Chemother 1978;13:1011-30.
2. Bernard J, Le Camus J, Sarrouy J, et al. [Toxic encephalopathy caused by mefloquine?] French. Presse Med 1978;16:1654-5.
3. Bjorkman A. Acute psychosis following mefloquine prophylaxis. Lancet 1989;2:865.
4. Phillips-Howard PA, ter Kuile FO. CNS adverse events associated with antimalarial agents. Fact or fiction? Drug Saf 1995;12:370-83.
5. Stuiver PC, Ligthelm RJ, Goud TJ. Acute psychosis after mefloquine. Lancet 1989;2:282.
6. Sturchler D, Handschin J, Kaiser D, et al. Neuropsychiatric side effects of mefloquine. N Engl J Med 1990;322:1752-3.
7. van Riemsdijk MM, Sturkenboom MC, Ditters JM, et al. Low body mass index is associated with an increased risk of neuropsychiatric adverse events and concentration impairment in women on mefloquine. Brit J Clin Pharmacol 2004;57:506-12.
8. Durrheim DN, Gammon S, Waner S, Braack LE. Antimalarial prophylaxis-use and adverse events in visitors to the Kruger National Park. S African Med J 1999;89:170-5.
9. Hennequin C, Bouree P, Bazin N, Bisaro F, Feline A. Severe psychiatric side effects observed during prophylaxis and treatment with mefloquine. Arch Intern Med 1994;154:2360-2.
10. Product information. Lariam (mefloquine). Nutley, NJ: Hoffman-LaRoche, August 2004.
11. Patchen LC, Campbell CC, Williams SB. Neurologic reactions after a therapeutic dose of mefloquine. N Engl J Med 1989;321:1415-6.
12. Rouveix B, Bricaire F, Michon C, et al. Mefloquine and an acute brain syndrome. Ann Intern Med 1989;110:577-8.
13. Lapras J, Vighetto A, Trillet M, Garin JP. [Transient disorders of memory after a malaria attack. Caused by mefloquine?] French (letter). Presse Med 1989;18:776.
14. Evans RL, Khalid S, Kinney JL. Antimalarial psychosis revisited. Arch Dermatol 1984;120:765-7.
15. Sapp OL 3rd. Toxic psychosis due to quinacrine and chloroquine. JAMA 1964;187:373-5.
16. Mustakallio KK, Putkonen T, Pihkanen TA. Chloroquine psychosis? Lancet 1962;2:1387-8.
17. Rab SM. Two cases of chloroquine psychosis (letter). Br Med J 1963;5340:1275.
18. Brookes D. Chloroquine psychosis (letter). Br Med J 1966;1:983.
19. Lindenmayer JP, Vargas P. Toxic psychosis following use of quinacrine. J Clin Psychiatry 1981;42:162-4.
20. Rockwell DA. Psychiatric complications with chloroquine and quinacrine. Am J Psychiatry 1968;124:1257-60.
21. Gaskill HS, Fitz-Hugh T. Toxic psychosis following atabrine. Bull US Army Dept 1945;86:63-9.
22. Dornhurst AC, Robinson B. Chloroquine psychosis? Lancet 1963;1:108.
23. Kabir SM. Chloroquine psychosis. Trans R Soc Trop Med Hyg 1969;63:549.
24. Bomb BS, Bedi HK, Bharnagar LK. Chloroquine psychosis (letter). Trans R Soc Trop Med Hyg 1975;69:523.
25. Weinke T, Trautmann M, Held T, et al. Neuropsychiatric side effects after the use of mefloquine. Am J Trop Med Hyg 1991;45:86-91.
26. Meier CR, Wilcock K, Jick SS. The risk of severe depression, psychosis or panic attacks with prophylactic antimalarials. Drug Saf 2004;27:203-13.
27. Cook GC. Malaria prophylaxis. Mefloquine toxicity should limit its use to treatment alone. BMJ 1995;311:190-1.
28. Bradley DJ, Warhurst DC. Malaria prophylaxis: guidelines for travellers from Britain. BMJ 1995;310:709-14.
29. Javorsky DJ, Tremont G, Keitner GI, Parmentier AH. Cognitive and neuropsychiatric side effects of mefloquine (letter). J Neuropsychiatry Clin Neurosci 2001;13:302.
30. World MJ. Malaria remains a military medical problem. J R Army Med Corps 2001;147:274-80.
31. Borruat FX, Nater B, Robyn L, Genton B. Prolonged visual illusions induced by mefloquine (Lariam): a case report. J Travel Med 2001;8:148-9.
32. Ingram RJ, Ellis-Pegler RB. Malaria, mefloquine and the mind. N Z Med J 1997;110:137-8.
33. Labbe T. Suicides in Iraq, questions at home. Washington Post, February 19, 2004.
34. International, U.P. DOD now eyes Lariam in suicides. Military.Com, February 26, 2004. www.military.com/NewsContent/0,13319,FL_ lariam_022604,00. html (accessed 2004 Aug 21).
35. White N. Assessment of the pharmacodynamic properties of antimalarial drugs in vivo. Antimicrob Agents Chemother 1997;41:1413-22.
36. Preboth M. CDC report on US incidence of malaria. Am Fam Physician, April 15, 2002.
37. Hisaeda H, Yasutomo K. Development of malaria vaccines that block transmission of parasites by mosquito vectors. J Med Invest 2002;49:118-23.
38. McDonald G. The epidemiology and control of malaria. Oxford, UK: Oxford University Press, 1957.
39. Petersen E. Malaria chemoprophylaxis: when should we use it and what are the options? Expert Rev Anti Infect Ther 2004;2:119-32.
40. Kofoed K, Petersen E. The efficacy of chemoprophylaxis against malaria with chloroquine plus proguanil, mefloquine, and atovaquone plus proguanil in travelers from Denmark. J Travel Med 2003;10:150-4.
41. Barrett PJ, Emmins PD, Clarke PD, Bradley DJ. Comparison of adverse events associated with the use of mefloquine and combination of chloroquine and proguanil as antimalarial prophylaxis: postal and telephone survey of travellers. BMJ 1996;313:525-8.
42. Huzly D, Schonfeld C, Beuerle W, Bienzle U. Malaria chemoprophylaxis in German tourists: a prospective study on compliance and adverse reactions. J Travel Med 1996;3:148-55.
43. Kain KC, Shanks GD, Keystone JS. Malaria chemoprophylaxis in the age of drug resistance. I. Currently recommended drug regimens. Clin Infect Dis 2001;33:226-34.
44. CDC, Travelers' health. www.cdc.gov/travel/regionalmalaria (accessed 2005 Jul 28).
45. Phillips-Howard PA, Behrens RH, Dunlop J. Stevens-Johnson syndrome due to pyrimethamine/sulfadoxine during presumptive self-therapy of malaria (letter). Lancet 1989;2:803-4.
46. Revised recommendations for preventing malaria in travelers to areas with chloroquine-resistant Plasmodium falciparum. MMWR Morb Mortal Wkly Rep 1985;34:185-90.
47. Hatton CS, Peto TE, Bunch C, et al. Frequency of severe neutropenia associated with amodiaquine prophylaxis against malaria. Lancet 1986;1:411-4.
48. Ognibene A. Agranulocytosis due to dapsone. Ann Intern Med 1970;72:521-4.
49. Friman G, Nystrom-Rosander C, Jonsell G, Bjorkman A, Lekas G, Svendsrup B. Agranulocytosis associated with malaria prophylaxis with maloprim. BMJ 1983;286:1244-5.
50. Hardwicke CJ. The World Health Organization and the pharmaceutical industry: common areas of interest and differing views. Adverse Drug React Toxicol Rev 2002;21:51-99.
51. Rather D, Pelley S, Simon B. Lariam's psychotic side effects. CBS News, 60 Minutes II, January 29, 2003. Transcript available at www.cbsnews.com.
52. Duffy A, Blanchfield M. Military probes malaria drug: MP says drug linked to Somalia incidents. The Ottawa Citizen, April 16, 1997.
53. Worthington P. Did we poison our Somalia soldiers? Toronto, Canada: The Edmonton Sun, January 3, 1998.
54. Corbett EL, Doherty JP, Behrens RH. Adverse events associated with mefloquine: study in returned travellers confirms authors' findings (letter). BMJ 1996;313:1552.
55. Rowlands B. A better pill for preventing malaria. London, UK: The Daily Telegraph, April 27, 2001.
56. World Health Organization. Review of central nervous system adverse events related to the antimalarial drug, mefloquine (1985-1990). Washington, DC: National Library of Medicine, 1995;91:1063.
57. FDA requires warning on anti-malaria drug Lariam. Consumer Reports, January 2004.
58. Taylor WR, White NJ. Antimalarial drug toxicity: a review. Drug Saf2 004;27:25-61.
59. Lobel HO, Bernard KW, Williams SL, Hightower AW, Patchen LC, Campbell CC. Effectiveness and tolerance of long-term malaria prophylaxis with mefloquine. Need for a better dosing regimen. JAMA 1991;265:361-4.
60. Thompson E. Assign mental-health workers to combat units. Army Times Associated Press. www.armytimes.com, November 8, 2002 (accessed 2004 Jul 28).
61. Hotopf M, David A, Hull L, Nikalaou V, Unwin C, Wessely S. Risk factors for continued illness among Gulf War veterans: a cohort study. Psychol Med 2004;34:747-54.
62. Jones E, Hodgins-Vermaas R, McCartney H, et al. Post-combat syndromes from the Boer war to the Gulf War: a cluster analysis of their nature and attribution. BMJ 2002;324:321-4. Erratum 2002;324:397.
63. Corominas N, Gascon J, Mejias T, et al. [Adverse effects associated with antimalarial chemoprophylaxis] Spanish. Med Clin (Barc) 1997;108:772-5. Errata 1997;109:299,462.
64. van Riemsdijk MM, Ditters JM, Sturkenboom MC, et al. Neuropsychiatric events during prophylactic use of mefloquine before travelling. Eur J Clin Pharmacol 2002;58:441-5.
65. van Riemsdijk MM, Ditters JM, Sturkenboom MC, et al. Neuropsychiatric effects of antimalarials. Eur J Clin Pharmacol 1997;52:1-6.
66. Bem JL, Kerr L, Stuerchler D. Mefloquine prophylaxis: an overview of spontaneous reports of severe psychiatric reactions and convulsions. J Trop Med Hyg 1992;95:167-79.
67. Schlagenhauf P, Steffen R, Lobel H, et al. Mefloquine tolerability during chemoprophylaxis: focus on adverse event assessments, stereochemistry and compliance. Trop Med Int Health 1996;1:485-94.
68. Phillips MA, Kass RB. User acceptability patterns for mefloquine and doxycycline malaria chemoprophylaxis. J Travel Med 1996;3:40-5.
69. Gutierrez-Lobos K, Scherer M, Anderer P, Katschnig H. The influence of age on the female/male ratio of treated incidence rates in depression. BMC Psychiatry 2002;2:3.
70. Grant BF, Hasin DS, Stinson FS, et al. Prevalence, correlates, and disability of personality disorders in the United States: results from the national epidemiologic survey on alcohol and related conditions. J Clin Psychiatry 2004;65:948-58.
71. Seedat S, Stein DJ, Carey PD. Post-traumatic stress disorder in women: epidemiological and treatment issues. CNS Drugs 2005;19:411-27.
72. Steffen R, Fuchs E, Schildknecht J, et al. Mefloquine compared with other malaria chemoprophylactic regimens in tourists visiting east Africa. Lancet 1993;341:1299-303.
73. Traer-Clark L. Adverse events associated with mefloquine. Manufacturer should also give incidence of "severe" adverse events (letter). BMJ 1996;313:1553.
74. Jensen JJ. [Neuropsychiatric adverse effects are often severe and persistent long after withdrawal of the drug] Danish (letter). Ugeskrift for Laeger 1998;160:2413.
75. CIOMS Working Group Report. Guidelines for preparing core clinical-safety information on drugs. Geneva, Switzerland, 1998. www.cioms.ch/ frame_publications.htm (accessed 2005 Dec 15).
76. Boudreau E, Schuster B, Sanchez J, et al. Tolerability of prophylactic Lariam regimens. Trop Med Parasitol 1993;44:257-65.
77. Bunnag D, Malikul S, Chittamas S, et al. Fansimef for prophylaxis of malaria: a double blind randomized, lacebo controlled trial. Southeast Asian J Trop Med Public Health 1992;23:777-82.
78. Carme B, Peguet C, Nevez G. Compliance with and tolerance of mefloquine and chloroquine + proguanil malaria chemoprophylaxis in French short-term travellers to sub-Saharan Africa. Trop Med Int Health 1997;2:953-6.
79. Kollaritsch H, Que JU, Kunz C, Wiedermann G, Herzog C, Cryz SJ Jr. Safety and immunogenicity of live oral cholera and typhoid vaccines administered alone or in combination with antimalarial drugs, oral polio vaccine, or yellow fever vaccine. J Infect Dis 1997;175:871-5.
80. Davis TM, Dembo LG, Eddie SA, Hewitt BJ, Hislop RG, Batty KT. Neurological, cardiovascular and metabolic effects of mefloquine in healthy volunteers: a double-blind, placebo-controlled trial. Br J Clin Pharmacol 1996;42:415-21.
81. Croft AM, Clayton TC, World MJ. Side effects of mefloquine prophylaxis for malaria: an independent randomized controlled trial. Trans R Soc Trop Med Hyg 1997;91:199-203.
82. Overbosch D, Schilthuis H, Bienzle U, et al. Atovaquone-proguanil versus mefloquine for malaria prophylaxis in nonimmune travelers: results from a randomized, double-blind study. Clin Infect Dis 2001;33:1015-21.
83. Schlagenhauf P, Tschopp A, Johnson R, et al. Tolerability of malaria chemoprophylaxis in non-immune travellers to sub-Saharan Africa: multicentre, randomised, double blind, four arm study. BMJ 2003;327:1078.
84. Beecher H. Measurement of subjective responses. Oxford: Oxford University Press, 1959.
85. Wolf S, Wolff HG. Human gastric function: an experimental study of a man and his stomach. Oxford: Oxford University Press, 1943.
86. Reams GG. Review of malaria prophylactic drugs for performance effects in naval aviators. Aviation Space Environ Med 1989;60(7 pt 2):A77-9.
87. Shamiss A, Atar E, Zohar L, Cain Y. Mefloquine versus doxycycline for malaria prophylaxis in intermittent exposure of Israeli Air Force aircrew in Rwanda. Aviation Space Environ Med 1996;67:872-3.
88. Ohrt C, Richie TL, Widjaja H, et al. Mefloquine compared with doxycycline for the prophylaxis of malaria in Indonesian soldiers. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1997;126:963-72.
89. Schlagenhauf P, Lobel H, Steffen R, et al. Tolerance of mefloquine by SwissAir trainee pilots. Am J Trop Med Hyg 1997;56:235-40.
90. Meszaros K. Acute psychosis caused by mefloquine prophylaxis (letter)? Can J Psychiatry 1996;41:196.
91. Siegel S. State dependent learning and morphine tolerance. Behav Neurosci 1988;102:228-32.
92. Earleywine M, Finn PR. Compensatory responses to placebo vary with presumed personality "risk" for alcoholism and drinking habits. Int J Addiction 1994;29:583-91.
93. Salgado JV, Hetem LA, Vidal M, Graeff FG, Danion JM, Sandner G. Reduction of latent inhibition by D-amphetamine in a conditioned suppression paradigm in humans. Behav Brain Res 2000;117:61-7.
94. Barrett JE. Modification of the behavioral effects of drugs by environmental variables. In: Seiden LS, Balster RL, eds. Behavioral pharmacology: the current status. New York: Arthur A Liss Publishing, 1985:7-22.
95. Dow GS, Hudson TH, Vahey M, Koenig ML. The acute neurotoxicity of mefloquine may be mediated through a disruption of calcium homeostasis and ER function in vitro. Malaria J 2003;2:1-14.
96. Loefler I. Mefloquine and anticoagulant interaction. J Travel Med 2003;10:194-5.
97. O'Shaughnessy TJ, Zim B, Ma W, et al. Acute neuropharmacologic action of chloroquine on cortical neurons in vitro. Brain Research 2003;959:280-6.
98. Gribble FM, Davis TM, Higham CE, Clark A, Ashcroft FM. The antimalarial agent mefloquine inhibits ATP sensitive K-channels. Br J Pharmacol 2000;131:756-60.
99. Davis KL, Berger PA. Pharmacological investigations of the cholinergic imbalance hypotheses of movement disorders and psychosis. Biol Psychiatry 1978;13:23-49.
100. Wright CE, Sabine JC. Cholinesterases of human erythrocytes and plasma and their inhibition by antimalarial drugs. J Pharmacol Expt Therapeu 1948;91:230-9.
101. Speich R, Haller A. Central anticholinergic syndrome with the antimalarial drug mefloquine. N Engl J Med 1994;331:57-8.
102. Croft AM, Herxheimer A. Adverse effects of the antimalaria drug mefloquine: due to primary liver damage with secondary thyroid involvement? BMC Public Health 2002;2:6.
103. Kollaritsch H, Karbwang J, Wiedermann G, Mikolasek A, Na-Bangchang K, Wernsdorfer WH. [Mefloquine concentration profiles during prophylactic dose regimens] German. Wien Klin Wochenschr 2000;112:441-7.
104. Ryan ET, Kain KC. Health advice and immunization for travelers. N Engl J Med 2000;342:1716-25.
105. Shanks GD, Karwacki JJ, Singharaj P. Malaria prophylaxis during military operations in Thailand. Mil Med 1989;154:500-2.
106. Fontanet AL, Houze S, Keundjian A, et al. Efficacy of antimalarial chemoprophylaxis among French residents travelling to Africa. Trans R Soc Trop Med Hyg 2005;99:91-100.
107. Chambers J. Military aviators, special operations forces, and causal malaria prophylaxis. Mil Med 2003;168:1001-6.
108. Dupouy-Camet J, Yera H, Tourte-Schaeffer C. Problems in prescribing malaria chemoprophylaxis for travelers. Fundam Clin Pharmacol 2003;17:161-9.
109. Bradley DJ, Bannister B; Health Protection Agency Advisory Committee on Malaria Prevention for UK Travellers. Guidelines for malaria prevention in travellers from the United Kingdom for 2003. Commun Dis Pub Health 2003;6:180-99.